Congenital Hyperinsulinism Treatment Market size, share, demand and Opportunities Analysis by 2032 | Novartis AG , Eisai Co., Ltd., Bristol-Myers Squibb Company , Merck & Co., Inc
Congenital hyperinsulinism (CHI) is a rare disorder of the pancreas, which is caused by an overproduction of insulin by the beta cells of the pancreas. It is a rare but serious condition, which can lead to episodes of hypoglycemia (low blood sugar) and can be life threatening. Download Free Sample of Report – https://www.globalinsightservices.com/request-sample/GIS25789 The goal of treatment for CHI is to reduce the body’s insulin production to a safe and normal level. The first step in treating CHI is to identify the underlying cause. Depending on the cause, treatment may include medications, surgery, or other treatments. Medications are the most common treatment for CHI. Medications such as diazoxide, octreotide, and somatostatin are used to reduce insulin production. These medications may be given as a single dose or as a continuous infusion. Surgery is another option for CHI. In some cases, the area of the pancreas that is causing the overproduction of insulin can be s...